Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

NCT ID: NCT03792503

Last Updated: 2024-02-28

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-02-28
• Study Completion Date: 2022-02-28

Brief Summary

In order to further improve the therapeutic efficacy of advanced no-squamous non-small cell lung cancer patients, improve the life cycle, this study will take the standard after treatment pemetrexed combined other anti-angiogenesis drugs to maintain as the direction, so as to provide more over the evidence for the treatment of advanced NSCLC.

Detailed Description

In patients with advanced non-squamous non-small cell lung cancer, patients receiving pemetrexed and platinum-based chemotherapy after 4 cycles of non-progressive evaluation were treated with pemetrexed plus apatinib. Until the disease progresses, there are intolerable side effects or the patient requests to withdraw from the study. It is planned to include 20 subjects.

Dosing regimen： Apatinib 500mg po qd (If there is a 3-4 degree toxic side reaction after 14 days of administration, the dose can be lowered to 250mg qd); Pemetrexed 500 mg/m2 d1×q3w; Until the patient progresses, the toxicity is intolerable, the patient withdraws his knowledge, or the investigator judges that the medication must be discontinued.

Conditions

Advanced Non-squamous Non-small-cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Apatinib，Pemetrexe

Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd

Group Type: EXPERIMENTAL

Apatinib

Intervention Type: DRUG

Apatinib 500 mg Po qd

Pemetrexed

Intervention Type: DRUG

Pemetrexe 500 mg/m2 d1×q3w

Interventions

Apatinib

Apatinib 500 mg Po qd

Intervention Type: DRUG

Pemetrexed

Pemetrexe 500 mg/m2 d1×q3w

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Stage IV non-squamous non-small cell lung cancer diagnosed by pathology.

2. At least one measurable lesion.

3. If the genetic test (EGFR/ALK) is an EGFR-sensitive mutation or an ALK fusion gene-positive patient, it is necessary to receive targeted therapy for the first-line treatment; if there is no mutation, it is necessary to be a first-line patient.

4. Pemetrexed combined platinum induction chemotherapy after 4 cycles of RECIST curative effect evaluation of patients who were not progress.

5. Gender is not limited, age: ≥ 18 years old.

6. ECOG PS: 0-2 points.

7. Estimated lifetime ≥3 months

8. Organ function levels meet the following criteria:

• Blood routine examination standards must meet: ANC≥1.5×109/L, PLT≥100×109/L, Hb≥100g/L (No blood transfusion and blood products within 14 days, not corrected by G-CSF and other hematopoietic stimulating factors).
• Biochemical examination must be in accordance with the following criteria: TBIL<1.5×ULN, ALT, AST and ALP<2.5×ULN, BUN and Cr≤1×ULN or Endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula).

9. Women of childbearing age must have reliable contraceptive measures, or in the group of 7 days before the pregnancy test (serum or urine), and the results were negative, and willing to during the test and the last for 8 weeks after experimental drug using appropriate methods of contraception.For men, must be agreed to at the end of the experiments and tests of giving drugs after 8 weeks using appropriate methods of contraception or has sterilization surgery.

10. Subjects were willing to join in this study, signed informed consent, good adherence, cooperate with the follow-up.

Exclusion Criteria

1. Squamous cell carcinoma (including adenosquamous carcinoma), small cell lung cancer (including small cell carcinoma and non-small cell mixed lung cancer).

2. Patient gene detection is EGFR sensitive mutation, or positive for ALK fusion gene.

3. Symptomatic brain metastasis (a patient with brain metastases who completed treatment and had stable symptoms 21 days before enrollment can be enrolled, but need to be confirmed by brain MRI, CT or venography to have no cerebral hemorrhage symptoms).

4. Imaging (CT or MRI) showed tumor lesions ranging from ≤ 5 mm to large vessels, or central tumors that invaded local large blood vessels; or showed significant pulmonary cavitary or necrotizing tumors.

5. Hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) that is still uncontrollable using a combination of two antihypertensive drugs.

6. Have the following cardiovascular diseases: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grade III to IV cardiac insufficiency, Or cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) <50%.

7. Patients with a history of pulmonary interstitial disease or a patient with pulmonary interstitial disease.

8. Abnormal coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy.

9. There is obvious cough blood in the 2 months before enrollment, or the daily hemoptysis amount is 2.5ml or more.

10. Into the group of the first 3 months there have been significant clinical significance of bleeding symptoms or have definite bleeding tendency.

11. Events of arterial/venous thrombosis occurring within 12 months prior to enrollment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism,etc.

12. Known hereditary or acquired bleeding and thrombophilia (such as hemophilia patients, coagulopathy, thrombocytopenia, hypersplenism, etc.)

13. Long-term unhealed wound or fracture.

14. Major surgery or severe traumatic injury, fracture or ulceration within 4 weeks of enrollment.

15. Factors that have a significant impact on oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction.

16. Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months prior to enrollment.

17. Urine routine indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0 g.

18. Has a history of psychiatric drugs abuse and can't quit or have a mental disorder.

19. Participated in other clinical trials of anti-tumor drugs within 4 weeks prior to enrollment.

20. Previous or concurrent with other unhealed malignant tumors, except for cured skin basal cell carcinoma, cervical carcinoma in situ, and superficial bladder cancer.

21. Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures.

22. The investigator judges other conditions that may affect the conduct of the clinical study and the determination of the results of the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xinqiao Hospital of Chongqing

OTHER

Sponsor Role: lead

Responsible Party

Jianguo Sun

Deputy director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Xinqiao Hospital of Chongqing

Chongqing, , China

Countries

China

Other Identifiers

XQonc-011

Identifier Type: -

Identifier Source: org_study_id